#United States #Los Angeles #Epilepsy #Neurelis #VALTOCO

Neurelis Presents Innovative Findings at the American Epilepsy Society Annual Meeting 2024

Neurelis, Inc. recently highlighted its array of significant studies focusing on seizure cluster treatments at the American Epilepsy Society (AES) Annual Meeting, occurring from December 6-10, 2024, in Los Angeles. The event has long served as a vital platform for the epilepsy community to discuss the latest advancements in research and clinical practice.

Neurelis showcased ten poster presentations detailing the use of VALTOCO (diazepam nasal spray), an immediate-use medication aimed at managing seizure clusters. This groundbreaking research includes comprehensive analyses related to pharmacokinetics, safety assessments, and potential implications for patients experiencing seizures in clinical settings.

Pivotal Research Findings

1. Recommendations for Acute Cluster Treatment: One of the compelling presentations draws on data from a long-term safety study of diazepam nasal spray. It emphasizes the importance of promptly managing acute seizure situations. The findings suggest that diazepam nasal spray can effectively terminate acute seizure clusters, ensuring a more straightforward approach to managing patient care during such episodes.

2. Animal Studies on Disease Modification: Another noteworthy study focused on a preclinical model using rats demonstrated how diazepam may display potential disease-modifying effects. The results revealed decreased severity and frequency of seizures, indicating the drug's potential to alter the course of epilepsy treatment positively.

3. Children's Safety Profile: Specifically addressing the younger demographic, a study evaluated the safety and pharmacokinetic characteristics of diazepam nasal spray for children aged 2-5. The analysis confirmed that the safety profile for this age group closely aligns with that established for older patients, underscoring the medication's broad applicability.

The presentations have sparked much discussion among healthcare professionals, researchers, and caregivers about the potential impact of these findings on improving treatment options for epilepsy patients.

Valuable Experiences Shared

Dr. Adrian L. Rabinowicz, Chief Medical Officer at Neurelis, emphasized the commitment to enhancing the quality of life for those living with epilepsy. He expressed pride in the volume and significance of the studies presented, remarking, "The AES Annual Meeting is a crucial opportunity for the epilepsy community to connect around vital research and innovations. We are committed to advancing treatment options that empower both patients and caregivers."

Another notable presentation focused on developing self-management tools for individuals dealing with seizure clusters. This evidence-based approach aims to integrate immediate-use seizure medications into a broader self-management framework designed for epilepsy patients, enhancing their ability to manage their condition actively.

Conclusion

Neurelis' aggressive focus on submissions at the AES Annual Meeting reinforces its role as a key player in the landscape of epilepsy treatment. By prioritizing research that addresses immediate medical needs and exploring the implications of long-term treatment through innovative therapies, Neurelis remains dedicated to delivering innovative solutions to enhance the quality of care for individuals with epilepsy. As the discussions continue, it is clear that the future of epilepsy treatment may be shaped by the findings presented at this significant event.

For more information about Neurelis and its products, particularly VALTOCO, a detailed account can be found at Neurelis Medical Affairs.